Using Hashimoto thyroiditis as gold standard to determine the upper limit value of thyroid stimulating hormone in a Chinese cohort by unknown
RESEARCH ARTICLE Open Access
Using Hashimoto thyroiditis as gold
standard to determine the upper limit
value of thyroid stimulating hormone
in a Chinese cohort
Yu Li1†, Dong-Ning Chen1†, Jing Cui1†, Zhong Xin2, Guang-Ran Yang2, Ming-Jia Niu3 and Jin-Kui Yang2*
Abstract
Background: Subclinical hypothyroidism, commonly caused by Hashimoto thyroiditis (HT), is a risk factor for
cardiovascular diseases. This disorder is defined as merely having elevated serum thyroid stimulating hormone
(TSH) levels. However, the upper limit of reference range for TSH is debated recently. This study was to determine
the cutoff value for the upper normal limit of TSH in a cohort using the prevalence of Hashimoto thyroiditis as
“gold” calibration standard.
Methods: The research population was medical staff of 2856 individuals who took part in health examination
annually. Serum free triiodothyronine (FT3), free thyroxine (FT4), TSH, thyroid peroxidase antibody (TPAb),
thyroglobulin antibody (TGAb) and other biochemistry parameters were tested. Meanwhile, thyroid ultrasound
examination was performed. The diagnosis of HT was based on presence of thyroid antibodies (TPAb and
TGAb) and abnormalities of thyroid ultrasound examination. We used two different methods to estimate the
cutoff point of TSH based on the prevalence of HT.
Results: Joinpoint regression showed the prevalence of HT increased significantly at the ninth decile of TSH
value corresponding to 2.9 mU/L. ROC curve showed a TSH cutoff value of 2.6 mU/L with the maximized
sensitivity and specificity in identifying HT. Using the newly defined cutoff value of TSH can detect patients
with hyperlipidemia more efficiently, which may indicate our approach to define the upper limit of TSH can
make more sense from the clinical point of view.
Conclusions: A significant increase in the prevalence of HT occurred among individuals with a TSH of 2.6–2.9 mU/L
made it possible to determine the cutoff value of normal upper limit of TSH.
Background
Patients with subclinical hypothyroidism have normal
level of serum thyroid hormones (T4, T3, FT3, FT4) and
elevated TSH. These patienshave a higher incidence of
lipid abnormalities, coronary heart disease, psychiatric
disorders and pregnancy complications [1–9], although
their clinical symptoms are very mild. Proper screening
and treatment of these patients may help to improve the
adverse outcome of the involving diseases. Therefore, to
define the upper limit of TSH precisely had an import-
ant role in detecting patients who had mild thyroid
dysfunction and might benefit from early intervention.
The upper limit of reference range for “normal”
TSH has been the focus of debate in the recent dec-
ade. Some authors insisted on the conventional value
of 4.0–5.0 mU/L as the upper limit of normal thyroid
stimulating hormone (TSH) [10], others suggested it
narrowed to 2.5–3.0 mU/L [11]. As mentioned in the
National Academy of Clinical Biochemistry (NACB)
guideline, more than 95 % of normal individuals had
TSH below 2.5 mU/L. There were even data showing
that African-Americans had very low incidence of HT
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with a mean TSH level of 1.18 mU/L This value
maybe the “true normal” upper limit for TSH, be-
cause African-Americans have very low prevalence of
Hashimoto thyroiditis (HT) to elevate TSH [11].
Another question was put forward that which was
the true set point of normal upper limit. Which cen-
tile (90, 95 or 99th) should be the real normal limit?
The approximate questions related to glycemic threshold
for diagnosing diabetes were already answered by using
diabetic retinopathy (DR) as “gold” calibration standard
[12]. Referring to that and based on the correlation
between HT (as end-point) and TSH value, we tried using
the prevalence of HT as the calibration standard to deter-
mine the upper limit of TSH.
Methods
Research population
A total of 2856 medical staffs with age between 20 and
60 years old participated in a health examination in the
year of 2013 were included in our research. Question-
naires related to medication history and other health-
related behaviors were completed beforehand. Blood
sampling was performed in the morning after eight
hours of fasting, followed by the detection of height,
weight, waist-to-hip ratio (WHR), blood pressure and
physical examinations.
The study was conducted with the approval of the
Ethics Committee of Beijing Tongren Hospital, Capital
Medical University.
Laboratory assessments
Blood samples were collected for testing thyroid func-
tion including serum free triiodothyronine (FT3), free
thyroxine (FT4) and TSH, thyroid peroxidase antibody
(TPAb), thyroglobulin antibody (TGAb) and other bio-
chemistry parameters including total cholesterol (TC),
triglyceride (TG), low density lipoprotein cholesterol
(LDL),, fasting plasma glucose (FPG), uric acid (UA),
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), creatinine (Cr) and carbon dioxide com-
bining power (CO2CP). Appliance for testing the above
mentioned biochemistry factors were Immunoassay
Systems (Beckman Coulter, UniCel DXI800).
The diagnostic criteria for HT
The diagnosis of HT was established by a combination
of presence of thyroid antibodies (TPAb and TGAb) and
abnormalities of thyroid sonogram including reduced
echo or diffused heterogeneity echo of thyroid with or
without nodularity [8]. Ultrasound examination of thy-
roid was performed by four experienced professional
ultrasound physicians. Consistent diagnosis standard
was used, including description for the size, nodules and
echo of the thyroid.
Framingham score
Framingham score (FS), a 10-year estimated risk of
CHD, was calculated by the equation including: age,
gender, blood pressure, smoking status and cholesterol
levels [13]. FS equaling to or over 9 was considered to
be a predictor for the higher CHD risk of over 5 %.
Statistical analysis
Unpaired t-test, Mann-Whitney U test or Pearson Chi-
square test was used to compare the difference between
cohorts with or without HT. We used two different
methods to estimate the cutoff point of TSH based on the
prevalence of HT: Joinpoint regression [14] and ROC curve
by maximizing the sensitivity and specificity. All statistical
analyses were conducted with the software package SPSS
version 13 for windows, and ljr package of R software
(http://www.r-project.org). A two-sided p value of less than
0.05 was considered to be statistically significant.
Results
Characteristics of the observed cohort
By the exclusion standard, those with abnormal thyroid
function (FT3 and FT4 out of the normal range), being
pregnant, taking thyroid related medicine, accepted thy-
roid operation and patients with personal history of
autoimmune disorders were excluded. A total number of
2856 individuals were included in the research, with the
average age of 36.0. The proportion of women (75 %)
was higher than men (25 %), which was consistent with
the gender characteristic of the medical staff in China.
The research population was further divided into HT
and non-HT groups. According to the diagnosis stand-
ard, 187 (7 %) in the observed cohort had HT (Table 1),
which comprised of 14 males and 173 females. The
prevalence of HT in females (8 %) was 4 times higher
than in males (2 %).
No significant differences between the HT and non-
HT groups were found in age, BMI, WHR, blood pres-
sure or biochemical parameters concerning liver func-
tion, blood glucose and lipid. However, serum creatinine
and uric acid were lower in HT group, which may be
related to the high prevalence of HT in females, because
females have relatively low level of serum creatinine and
uric acid than males.
The distribution of TSH in the total population and
subgroups (HT and non-HT group)
Although exclusion standard was used in our research to
get a relatively homogeneous cohort without overt thy-
roid diseases, the distribution of TSH still showed asym-
metrical curve with extension to the right side. We then
separated HT from the whole population, and the TSH
distribution of HT and non-HT groups was described in
Fig. 1. Non-HT group showed a more likely Gaussian
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curve, and the HT group showed an uneven curve with
more rightward trend representing higher TSH values.
The different centiles of TSH in both groups were listed
in Table 2. By ANOVA analysis, there was no statistically
significant influence of age to the upper limit of TSH in
our research population (P = 0. 5).
The prevalence of HT corresponding to each decile of
TSH value
A curve was drawn to describe the correlation between
HT and TSH value (Fig. 2). Each decile of TSH value
was marked in the X-axis, meanwhile the proportion
of participants with HT between each decile of TSH
was shown in Y-axis. The curve was relatively flat
when TSH <2.9 mU/L. Whereas the curve showed a
sharp increase at the ninth decile of TSH (corre-
sponding to TSH≧2.9 mU/L) The prevalence of HT
in the ninth decile was 21 %, while that in the eighth
decile was 8 %. Regression analysis showed a good
Joinpoint at the ninth decile (P = 0.0012). Logistic
regression models adjusted for sex, age, BMI, FT4,
systolic blood pressure and biochemical parameters
also confirmed a statistically significant difference for
the prevalence of HT below vs. above the cutoff
point for TSH value (OR 3.07 [95 % CI: 2.24–4.21];
P = 0.000).
ROC curve describing the cutoff value of TSH in detecting
participants with HT
When maximizing the sensitivity and specificity, the cut-
off value of TSH equaled to 2.6 mU/L, with the sensitiv-
ity of 52 % and the specificity of 77 %. The area under
the ROC curve was 66 % (95 % CI: 61.01–70.51) (Fig. 3).
The proportion of participants with HT was 4 % when
TSH was below 2.6 mU/L. As compared, when TSH was
above 2.6, the proportion of participants with HT was
14 % (P = 0.000 by Fisher’s exact test).
Table 1 Characteristics of observed cohort divided by the participants with Hashimoto thyroiditis (HT) or without HT (non-HT)
Non HT HT P
No 2669 187 —
Age (year) 35.90 (9.15) 36.99 (9.25) 0.117
Sex (M/F) 704/1965 14/173 <0.001**
TSH (μIU/l) 1.83 (0.01–26.36) 2.66 (0.01–39.96) 0.001*
Free triiodothyronine (pmol/l) 4.96 (0.68) 4.95 (0.92) 0.92
Free thyroid hormone (pmol/l) 10.58 (1.72) 10.36 (1.92) 0.12
BMI (kg/m2) 23.23 (3.61) 23.33 (3.31) 0.69
WHR 0.81 (0.07) 0.80 (0.06) 0.14
Systolic blood pressure (mmHg) 114.15 (13.95) 113.66 (13.61) 0.64
Diastolic blood pressure (mmHg) 73.22 (9.39) 72.87 (8.71) 0.60
Alanine aminotransferase (IU/l) 24.26 (17.40) 22.84 (12.04) 0.13
Aspartate aminotransferase (IU/l) 26.53 (9.68) 26.41 (7.73) 0.84
Blood urea nitrogen (mmol/l) 3.80 (1.05) 3.72 (0.99) 0.28
Creatinine (μmol/l) 65.54 (13.99) 60.09 (9.68) <0.001*
Total cholesterol (mmol/l) 4.64 (0.84) 4.65 (0.83) 0.87
Triglycerides (mmol/l) 1.10 (0.91) 1.04 (0.73) 0.34
LDL cholesterol (mmol/l) 2.89 (0.89) 2.88 (0.74) 0.87
HDL cholesterol (mmol/l) 1.45 (0.39) 1.47 (0.34) 0.45
Fasting plasma glucose (mmol/L) 5.33 (0.94) 5.24 (0.50) 0.16
Uric acid (mmol/L) 278.90 (74.60) 264.48 (67.47) 0.010
Values are mean(SD) or median (range). Comparison between any two groups by unpaired t-test, Mann-Whitney U test* or Pearson Chi-square test**. Data in bold
are statistically significant
Fig. 1 Distribution of thyroid stimulating hormone (TSH) in both
Hashimoto thyroiditis (HT) (− − −) and non-HT ( ̶̶̶̶ ̶̶̶̶ ̶̶̶̶ ̶̶̶̶ ̶̶̶̶̶̶̶̶ ̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶̶)̶ participants.
Curves were smoothed by the GraphPad Prism 5 software
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Comparison of metabolism-related parameters between
groups divided by different cutoff values of TSH
As shown in Table 3, the cutoff value of 2.9 mU/L
(based on the Joinpoint regression), and 2.6 mU/L
(based on the ROC curve analysis), and 4.5 mU/L (con-
ventionally accepted cutoff value) were used to
categorize the population. All three grouping methods
showed a higher probability of hyperlipidemia and a
higher Framingham Score in participants with TSH
above the cutoff point, and a relatively younger age in
participants with TSH below the cutoff point. As com-
pared to using 4.5 mU/L as the cutoff point, using
2.6 mU/L or 2.9 mU/L as the cutoff value of TSH can
detect more patients with abnormal TC and LDL. That
may tell us it’s more effective to apply the lowered cutoff
value of TSH for detecting patients with dyslipidemia.
Discussion
To get a more convincing reference range of TSH,
previous researchers used a more stringent standard
for screening the reference population proposed by
the NHANES III study [2], and more sensitive assays
were used to measure TSH of those reference individ-
uals. The upper limit of TSH was lowered to 3.6–
3.7 mU/L [3, 15]. It was believed that the skewing
right tail of the TSH distribution curve was caused by
the inclusion of those with occult thyroid dysfunc-
tions most representatively as HT. Besides, other fac-
tors such as gender and age are also critical to the
reference range of TSH [16]. In this study, age does
not serve as an influence factor to the upper limit of
TSH. The reason may be the research population was
a homogeneously young cohort. Besides, It is not an
iodine deficient area in Beijing. Therefore, the daily
iodine intake and total body iodine status should not
be a major factor to influence TSH value in our
research population. We aimed to clear up the con-
founding influence of those individuals with HT to
determine the cutoff point of TSH in our research
population.
If we defined the upper limit of normal TSH as the
95th centile as adopted by previous researchers, the
value would be 4.2, which could be comparable to most
publications and more approximate to the traditional
opinions insisting on 4.0–5.0 mU/L as the upper limit of
normal TSH.
However, there were still considerable proportion of
people with occult subclinical thyroid disease (mostly
HT) within the upper part of the normal TSH range.
Fig. 2 a The prevalence of HT corresponding to each decile of TSH value (Each point in the chart corresponded to the number labeled in X axis.
2.89 is the cutoff value of TSH revealed by joinpoint analysis). b The joinpoint regression analysis showed only one joinpoint was found.
This joinpoint presented in the ninth decile group, and the lower limit value of this group of 2.89 was taken as the cutoff
Table 2 Serum TSH levels (mU/L) in total population and
subgroups categorized by age
Percentile
Age (yr) Sample No. 2. 5th 5th Median 95th 97.5th
A. total
19–29 845 0.53 0.73 1.80 4.45 5.50
30–39 1060 0.51 0.73 1.85 4.42 4.98
40–49 662 0.61 0.73 1.94 4.99 5.61
50–59 289 0.65 0.70 1.92 5.45 7.49
B. non-HT
19–29 799 0.56 0.75 1.79 4.33 5.19
30–39 989 0.52 0.74 1,82 4.06 4.62
40–49 616 0.62 0.73 1.91 4.31 5.26
50–59 265 0.65 0.70 1.86 4.58 5.67
C. HT
19–29 46 0.37 0.74 2.33 8.48 21.67
30–39 71 0.02 0.46 2.43 9.50 18.86
40–49 46 0.03 0.33 3.29 8.34 24.26
50–59 24 0.56 0.73 3.17 14.77 15.50
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Whereas we expect the normal range as a tool to screen
out abnormal individuals. We tried an alternative
approach to exclude the influence to TSH value con-
founded by individuals with HT. Based on the fact that
TSH and the prevalence of HT was well correlated, we
used “the prevalence of HT” as a checkout factor to
determine the cutoff upper limit of TSH. Mimicking the
diagnostic methodology in determining glycemic thresh-
olds using DR as the checkout factor, we drew a curve
describing the correlation between the prevalence of HT
and TSH value. From this curve we got a turning point
at TSH 2.9 mU/L by Joinpoint regression analysis. The
prevalence of HT above this point was 14.5 % and much
higher than that below the cutoff point (4.6 %). Similarly,
ROC curve revealed a cutoff value of 2.6 mU/L, by
which we can effectively detect HT with the best sensi-
tivity and specificity.
These two measures showed very close results which
are more close to the proposal in recent NACB guideline
about narrowing the upper limit of TSH to 2.5 mU/L
[11]. As proposed by Surks [16], the normal range for
TSH should meet the needs to categorize population
into groups 1) normal, 2) those who need to be observed
closely and 3) those who need medication. Although the
lowered cutoff value of TSH may not be used as a treat-
ment threshold, it can help to find more patients with
occult subclinical thyroid diseases. If the limit was in-
creased to 4.5U/L, 2.2 % of individuals with HT would
be missed.
It has been indicated by several studies [17–19],
that elevated TSH within the normal range was posi-
tively related to lipid abnormalities or even to the
future occurring of hypertension and hyperlipidemia.
Likewise, we used the lowered cutoff value of TSH
to categorize population to watch if it made sense
concerning the metabolism parameters among
groups. As expected, people in the group with higher
TSH had a much higher age, higher rate of hyperlip-
idemia and a higher Framingham score. When the
cutoff value of 2.6 mU/L was used, it showed better
results with more significant difference between
groups concerning hyperlipidemia (hyper-TC, hyper-
LDL and hyper-TG). Meanwhile, if a lowered upper
limit of TSH was used, we can detect more patients
with hyperlipidemia with less missed diagnosis. The
Framingham score went higher with the increasing of
TSH. This was also consistent with Asvold’s observa-
tion [9] and suggested increased incidence of coron-
ary heart disease in population with SCH. Therefore,
a lowered upper limit of TSH can also help to detect
individuals with increased risk of ischemic heart
diseases effectively.
Table 3 Comparison of metabolism related parameters between groups divided by cutoff values of TSH based on different method
(using Joinpoint regression, ROC curve and conventional accepted value respectively)
Derivation of cutoff values Group No Age (mean(SD)) BMI ≧24 Hyper- TC Hyper-LDL-c Hyper-TG Hyper- FPG FS≧9
Joinpoint regression TSH < 2.9 2284 35.7 (9.1) 37 % 22 % 23 % 14 % 7 % 20 %
TSH≧2.9 572 36.9 (9.5) 35 % 27 % 27 % 18 % 8 % 23 %
P 0.009 0.49 0.021* 0.07 0.030* 0.46 0.18
ROC curve TSH < 2.6 2138 35.7 (9.1) 37 % 22 % 23 % 14 % 7 % 20 %
TSH≧2.6 718 36.8 (9.5) 36 % 28 % 27 % 17 % 8 % 23 %
P 0.008 0.44 <0.001* 0.007* 0.024* 0.21 0.034*
Conventional accepted TSH < 4.5 2714 35.9 (9.1) 37 % 23 % 24 % 15 % 7 % 20 %
TSH≧4.5 142 37.7 (10.2) 38 % 26 % 26 % 20 % 9 % 31 %
P 0.046 0.77 0.008* 0.50 0.09 0.39 0.003*
Values are means(SD) or probability. Comparison between any two groups by unpaired t-test, or Pearson Chi-square test*. Data in bold are statistically significant
FS Framingham score, LDL-c low-density lipoprotein cholesterol, TG triglyceride, FPG fasting plasma glucose
Fig. 3 ROC curve describing the cutoff value of TSH in detecting
participants with HT. When maximizing the sensitivity and specificity,
the cutoff value of TSH equaled to 2.6 mU/L, with the sensitivity of
52 % and the specificity of 77 %
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Certainly, there were several limitations in our study,
including the higher proportion of females in the re-
search population leading to a bias of TSH value which
may be caused by the higher prevalence of HT in
females. Secondly, the age of the research population
was no older than 60, so the conclusion may not be
applied to older people.
Conclusion
This study shows a high prevalence of HT occurred
among individuals with a TSH of 2.6–2.9 mU/L.
These values are possible to the “true” values of nor-
mal upper limit of TSH for Chinese population. From
the trend of higher abnormalities in metabolism-
related indicators and Framingham score with the ele-
vation of TSH, a proper cutoff value of normal upper
limit of TSH will be useful in patients with mild thy-
roid dysfunction.
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